- •Ospemifene is a novel selective estrogen receptor modulator for the treatment of vulvo-vaginal atrophy and dyspareunia.
- •This meta-analysis reviews all the published randomized controlled trials on the efficacy of ospemifene.
- •This drug seems to be an effective treatment for dyspareunia and vaginal dryness.
To evaluate the efficacy of ospemifene in treating dyspareunia associated with postmenopausal vulvo-vaginal atrophy (VVA).
A structured search was carried out in PubMed-Medlin, Embase, Cochrane Controlled Trials Register databases through to 31 July 2018. The search included the following terms: "Ospemifene", "vulvovaginal atrophy", "dyspareunia", “SERM” and "randomized controlled trial" (RCTs). Four outcomes were selected: vaginal pH; proportions of parabasal and superficial vaginal cells; and perception of the most bothersome symptom (vaginal dryness or dyspareunia). A random-effects model was used in the meta-analysis. Study quality and bias risk were assessed with the Cochrane tool.
Six RCTs comparing the efficacy of ospemifene against placebo after 12 and 52 weeks of treatment were included in the meta-analysis. At 12 weeks, changes in vaginal Ph (SMD: -0.96, 95% CI:-1.12 to –0.81; p < 0.0001), parabasal cells (SMD: -36.84 95% CI -46.95 to -26.72; p < 0.0001), superficial cells (SMD: 8.23, 95% CI 3.73–12.74, p < 0.0003), and dyspareunia (SMD= - 2.70, 95% CI - 2.88 to -2.52, p < 0.0001) indicated that ospemifene was more effective than placebo.
The present meta-analysis suggests that ospemifene 60 mg is associated with significant improvement in the morphological and physiological features of the vaginal mucosa that correlate with the symptoms associated with postmenopausal VVA.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Ospemifene: first global approval.Drugs. 2013; 73: 605-612
- Vulvovaginal atrophy.Mayo Clin. Proc. 2010; 85: 87-94
- The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe.Maturitas. 2013; 75: 373-379
- Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.Menopause. 2008; 15: 661-666https://doi.org/10.1097/gme.0b013e31815a5168
- The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.Sex. Med. 2014; 11: 487-497https://doi.org/10.1111/jsm.12377
- Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.Climateric. 2015; 19: 60-65https://doi.org/10.3109/13697137.2015.1113517
- Higgins J.P.T. Green S. Cochrane Handbook for Systematic Reviews of Interventions, v.5.1. Wiley-Blackwell, New Jersey2018 (updated March 2011. Cochrane Collaboration Web site. Available at:)
- Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.Menopause. 2003; 10: 433-439
- Ospemifene effectively treats vulvo- vaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.Menopause. 2010; 17: 480-486
- One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.Menopause. 2018; 20 (pp. 418/427)https://doi.org/10.1097/gme.0b013e31826d36ba
- Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.Climateric. 2014; 17: 173-182https://doi.org/10.3109/13697137.2013.834493
- Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.Menopause. 2018; 20 (pp. 623/630)https://doi.org/10.1097/gme.0b013e318279ba64
- Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment ovaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.Maturitas. 2014; 78: 91-98https://doi.org/10.1016/j.maturitas.2014.02.015
- In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer.J. Steroid Biochem. Mol. Biol. 2001; 77: 271-279
- Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.Climacteric. 2015; 18: 226-232
- A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses.PLoS One. 2013; 8
Published online: November 24, 2018
Accepted: November 22, 2018
Received in revised form: November 15, 2018
Received: November 9, 2018
© 2018 Published by Elsevier B.V.